GlassScriptPhysician profile
George J Baker
NPI 1467404905
$4,421.33
in general payments reported to CMS, 2019-2025
27 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,307 · 2022: $889 · 2023: $1,021 · 2024: $716 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $658.66 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $577.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $425.28 | 2021-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Abbvie INC. | $344.75 | 2021-2025 | |
| Amarin Pharma, INC. | $334.22 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $308.21 | 2021-2024 | Xarelto |
| Pfizer INC. | $307.47 | 2021-2024 | |
| Lilly USA, LLC | $300.70 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $223.67 | 2021-2024 | Prolia, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.73 | 2021-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $125.01 | 2021-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $124.25 | 2022-2025 | |
| Boston Scientific Corporation | $72.67 | 2023-2024 | Watchman Flx |
| Insulet Corporation | $61.12 | 2021 | |
| Almatica Pharma LLC | $45.29 | 2021-2023 | Gralise, Loreev Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $39.15 | 2021 | |
| Idorsia Pharmaceuticals US INC | $34.37 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $34.14 | 2022 | |
| Astellas Pharma US INC | $29.14 | 2021 | |
| Sumitomo Pharma America, INC. | $24.66 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $22.01 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.91 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.30 | 2021 | |
| Exact Sciences Corporation | $18.41 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $17.41 | 2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $17.01 | 2025 | Vyepti |
| Medtronic, INC. | $15.64 | 2025 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.